EGFR and non-small cell lung carcinoma: For instance, the mutational status of oncogenes such as KRAS and EGFR and ALK rearrangements have been revealed as predictive indicators of malignant disease, and new drugs such as inhibitors of these molecules have shown improvements in treatment outcomes of advanced NSCLC (Vincent et al. 2012).